But there is a non-statistical basis for concern: an ominous parallel with the financial environment that prevailed in the weeks leading up to the October 1987 stock-market crash. On that day - Black ...

Looking ahead to the third quarter, the analysts noted that guidance suggests higher AI investment spending, albeit supported ...

If any investor has stood the test of time, it’s Warren Buffett, and with good reason. For years, the “Oracle of Omaha” has ...

Q1 2026 Earnings Call Transcript August 1, 2025 RBC Bearings Incorporated beats earnings expectations. Reported EPS is $2.84, ...

Fortis Inc. (NYSE: FTS) Q2 2025 Earnings Call Transcript August 1, 2025 Fortis Inc. beats earnings expectations. Reported EPS ...

Operator: Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.

Key Points - Non-GAAP earnings per share were $0.74 for the fiscal second quarter ended June 30, 2025, beating estimates by $0.03 (non-GAAP). Revenue reached $1,140.4 million for the fiscal second ...

Key Points Earnings per share (Non-GAAP) were $0.94 in Q2 2025 beating the analyst estimate by 9.3% (non-GAAP) and the company exceeded its non-GAAP EPS outlook by $0.08. Net sales (GAAP) reached ...

Praxis Precision Medicine PRAX -4.09% Get Free Report will release its quarterly earnings report on Monday, 2025-08-04. Here's a brief overview for investors ahead of the announcement. Analysts ...

Management reaffirmed 2025 operating earnings per share guidance of $3.28 to $3.52, with a midpoint of $3.40. Ridge stated, "I'm highly confident in our ability to deliver on our financial plan, ...

Analysts are estimating that Castle Biosciences will report an earnings per share (EPS) of $-0.50. Investors in Castle Biosciences are eagerly awaiting the company's announcement, hoping for news of ...

Kellanova’s North American net sales in the second quarter fell 3.8% year over year to $1.59 billion from $1.66 billion. Organic net sales also were down 3.8% as volume dropped by the same percentage.